Treatment of advanced pancreatic cancer with epirubicin, 5- fluorouracil and l-leucovorin: A phase II study

Annals of Oncology

Volumn 8, Issue 8, 1997, Pages 797-799

  Raderer, M ^a   Kornek, G V ^a   Hejna, M H ^a   Weinlaender, G ^a   Vorbeck, F ^a   Fiebiger, W C C ^a   Scheithauer, W ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

1 leucovorin; 5 Fluorouracil; Epirubicin; Palliative chemotherapy; Pancreatic cancer

Indexed keywords

EPIRUBICIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PALLIATIVE THERAPY; PANCREAS CANCER; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS;

EID: 0030930136     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008276004552     Document Type: Article

References (13)

1. National Cancer Institute. Annual Cancer Statistics Review 1973-1988. Bethesda, MD: Department of Health and Human Services, 1991 (NIH Publication No. 91-2789).
2. Arbuck SG. Overview of chemotherapy for pancreatic cancer. Int J Pancreatol 1990; 7: 209-22.
3. Wright-Browne VM, Abbruzzese JL. Cancer of the pancreas. In: Rustgi AK (ed): Gastrointestinal Cancers: Biology, Diagnosis and Therapy. Philadelphia: Lippincott-Raven 1995; 325-40.
4. Moore M, Andersen J, Burris H et al. A randomized trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1995; 14; 199.
5. Crown J, Casper ES, Botet J et al. Lack of efficacy of high dose leucovorin andfluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9: 1682-6.
6. White JC, Bailey BD, Goldman ID. Lack of stereospecifity at carbon 6 of methyltetrahydrofolate transport in Ehrlich ascites tumor cells. Carrier mediatedtransport of both stereoisomers. J Biol Chem 1978; 253: 242-5.
7. Zittoun J. Pharmacokinetics and in vitro studies of 1-leucovorin. Comparison with the d- and d,l-leucovorin. Ann Oncol 1993; 4: 1-6 (Suppl2).
8. Rothenberg ML, Abbruzzese JL, Moore M et al. Rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996; 78: 627 (Suppl).
9. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
10. Glimelius B, Hoffman K, Sjödén PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 393-600.
11. Andre T, Lotz JP, Bouleuc C et al. Phase II trial of 5-fluorouracil. leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 1996; 7: 173-8.
12. Goldberg RM, O'Connell MJ, Wieand HS et al. A prospective randomized trial of intensive course 5-FU combined with a) the 1-isomer of intravenous leucovorin, b) oral (d,l) leucovorin or c) intravenous (d,l) leucovorin for the treatment of advanced colorectal cancer: A North Central cancer Treatment Group trial. Proc Am Soc Clin Oncol 1996; 15: 207.
13. Scheithauer W, Kornek G, Marczell A et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for treatment of advanced colorectal cancer: A randomized phase III study. J Clin Oncol 1997; 15 (in press).